Evidence map›Paper›PMID 26619358›Full record

ArticleNature neuroscience2016

Mapping DNA methylation across development, genotype and schizophrenia in the human frontal cortex.

Andrew E Jaffe, Yuan Gao, Amy Deep-Soboslay, Ran Tao, Thomas M Hyde, Daniel R Weinberger, Joel E Kleinman

Registry-linked trialAbstract read
In one paragraph

Article in Nature neuroscience, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03790085 (Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals), which is not on this map. Cited by 305 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
305citing papers in PubMed, 10 pooled it
24.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03790085 early_phase1unknown statusnot on this mapstarted 2018, after this paper: background citation

Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals

TypeinterventionalSponsorTianjin Medical University General HospitalRan2018 to 2020Enrolled2,700ConditionsSchizophrenia, Major Depressive Disorder, Anxiety DisordersArmsRisperidone, Olanzapine, Aripiprazole
3 · Its place in the literature

Who cites it

305 citing papers in PubMed, 10 syntheses or guidelines pooled it, 553 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Genome-wide DNA methylation differences in nucleus accumbens of smokers vs. nonsmokers.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Schizophrenia: from mechanism to therapy.Science China. Life sciences · 2026
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

245 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Andrew E JaffeLieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, Maryland, USA.ORCID http://orcid.org/0000-0001-6886-1454
Yuan GaoLieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, Maryland, USA.
Amy Deep-SoboslayLieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, Maryland, USA.
Ran TaoLieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, Maryland, USA.
Thomas M HydeLieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, Maryland, USA.
Daniel R WeinbergerLieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, Maryland, USA.
Joel E KleinmanLieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, Maryland, USA.
Johns Hopkins University · US

Funding

Establishing comprehensive and quantitative maps of DNA methylation in the develoR21MH102791 · NIMH · LIEBER INSTITUTE, INC. · PI JAFFE, ANDREW ELLIS · 2014 to 2015
$596k
NIMH NIH HHS 1R21MH102791NIMH NIH HHS R21 MH102791
6 · The paper itself

Abstract

DNA methylation (DNAm) is important in brain development and is potentially important in schizophrenia. We characterized DNAm in prefrontal cortex from 335 non-psychiatric controls across the lifespan and 191 patients with schizophrenia and identified widespread changes in the transition from prenatal to postnatal life. These DNAm changes manifest in the transcriptome, correlate strongly with a shifting cellular landscape and overlap regions of genetic risk for schizophrenia. A quarter of published genome-wide association studies (GWAS)-suggestive loci (4,208 of 15,930, P < 10(-100)) manifest as significant methylation quantitative trait loci (meQTLs), including 59.6% of GWAS-positive schizophrenia loci. We identified 2,104 CpGs that differ between schizophrenia patients and controls that were enriched for genes related to development and neurodifferentiation. The schizophrenia-associated CpGs strongly correlate with changes related to the prenatal-postnatal transition and show slight enrichment for GWAS risk loci while not corresponding to CpGs differentiating adolescence from later adult life. These data implicate an epigenetic component to the developmental origins of this disorder.

Indexed as

DNA MethylationGenotypeTissue BanksAge of OnsetCpG IslandsEpigenesis, GeneticFetal DevelopmentGenetic LociHuman DevelopmentHumansPrefrontal CortexSchizophreniaTranscriptome

Identifiers

PMID26619358
PMCPMC4783176
OpenAlexW2181445041

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.